US FDA criticises in vitro data claims in Altabax sales aid
This article was originally published in Scrip
Executive Summary
A GlaxoSmithKline sales brochure that highlighted in vitro data for the topical antibiotic Altabax (retapamulin ointment 1%) inappropriately broadened the product's indication and made unsubstantiated superiority claims, the US FDA has said.